Impairment of Tear-Production in Corneal Herpetic Diseases

1981 ◽  
pp. 215-219 ◽  
Author(s):  
C. C. Kok van Alphen ◽  
H. J. M. Völker-Dieben
Keyword(s):  
2007 ◽  
Vol 10 (3) ◽  
pp. 147-154 ◽  
Author(s):  
Tiffany Blocker ◽  
Allison Hoffman ◽  
David J. Schaeffer ◽  
Julia A. Wallin

1982 ◽  
Vol 93 (1) ◽  
pp. 84-87 ◽  
Author(s):  
Alfred Sommer ◽  
Nani Emran
Keyword(s):  

2010 ◽  
Vol 13 (1) ◽  
pp. 1-3 ◽  
Author(s):  
Masoud Selk Ghaffari ◽  
Abdolali Malmasi ◽  
Saied Bokaie

2011 ◽  
Vol 31 (4) ◽  
pp. 350-354 ◽  
Author(s):  
L.F. Conceição ◽  
A.P. Ribeiro ◽  
M.L.M. Torres ◽  
M.L.G. Lourenço ◽  
J.L. Laus

The study aimed to evaluate tear production by means of modified Schirmer tear tes-1 (mSTT-1) in neonate cats. Likewise, correlation between mSTT-1 and STT-1 was assessed in vitro. Standard SST strips were cut in half and after eye lid opening, tear production of neonates (n=15) was daily measured in both eyes (mSTT-1), until the 7th day, and at day 14, 21, and 28. Animals were daily weighted until 28 days of age. Results were compared statistically (P<0.05). During the first 7 days, the overall mSTT-1 mean was 0.76 wetting/minute. Significant differences between right and left eyes were not observed at any time point (P=1.00). Tear secretion increased significantly, from the 14th to 28th day, in comparison with 7 first days (P<0.05). Positive correlation between maturity parameters and tear secretion was observed (P<0.0001). Distance between slopes of each strip changed significantly (P<0.0001). It was concluded that tear secretion in the neonatal period of cats is very below the reference values described for young and adults of the same species. It is not possible to extrapolate results obtained with mSTT-1 to standard STT-1.


2019 ◽  
Vol 17 (1) ◽  
pp. 142-150 ◽  
Author(s):  
John D. Sheppard ◽  
Gail L. Torkildsen ◽  
Joel A. Geffin ◽  
Jung Dao ◽  
David G. Evans ◽  
...  

2012 ◽  
Vol 16 (3) ◽  
pp. 175-179 ◽  
Author(s):  
Enry Garcia da Silva ◽  
Lynne S. Sandmeyer ◽  
Juliet R. Gionfriddo ◽  
Fabiano Montiani-Ferreira ◽  
Paula D. Galera

Biomedicines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 129
Author(s):  
Min Song ◽  
Jide Tian ◽  
Blake Middleton ◽  
Cuong Q. Nguyen ◽  
Daniel L. Kaufman

Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by lymphocytic infiltrates in the salivary and lachrymal glands resulting in oral and ocular dryness. There are no clinically approved therapies to slow the progression of SS. Immune cells possess receptors for the neurotransmitter GABA (GABA-Rs) and their activation has immunoregulatory actions. We tested whether GABA administration has potential for amelioration of SS in NOD.B10-H2b and C57BL/6.NOD-Aec1Aec2 mice, two spontaneous SS models. Oral GABA treatment was initiated (1) after the development of sialadenitis but before the onset of overt symptoms, or (2) after the appearance of overt symptoms. When assessed weeks later, GABA-treated mice had greater saliva and tear production, as well as quicker times to salvia flow, in both SS mouse models. This was especially evident when GABA treatment was initiated after the onset of overt disease. This preservation of exocrine function was not accompanied by significant changes in the number or area of lymphocytic foci in the salivary or lachrymal glands of GABA-treated mice and we discuss the possible reasons for these observations. Given that GABA-treatment preserved saliva and tear production which are the most salient symptoms of SS and is safe for consumption, it may provide a new approach to help ameliorate SS.


Sign in / Sign up

Export Citation Format

Share Document